X. Perez

发表

Multiple roles for nicotine in Parkinson's disease.

M. Quik, N. Parameswaran, T. Bordia, 2009, Biochemical pharmacology.

Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human α-synuclein in mice

Erica L. Unger, A. Andrews, Yanqun Xu, 2006, Neurobiology of Disease.

Chronic Nicotine Exposure Depresses Dopamine Release in Nonhuman Primate Nucleus Accumbens

M. Quik, J. McIntosh, X. Perez, 2012 .

Determining Serotonin and Dopamine Uptake Rates in Synaptosomes Using High-Speed Chronoamperometry

A. Andrews, X. Perez, A. Bressler, 2007 .

Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

M. Quik, X. Perez, 2011, Molecular and cellular pharmacology.

Targeting nicotinic receptors for Parkinson's disease therapy.

M. Quik, T. Bordia, Luping Z. Huang, 2011, CNS & neurological disorders drug targets.

Role of alpha6 nicotinic receptors in CNS dopaminergic function; relevance to addiction and neurological disorders

S. Grady, M. Quik, X. Perez, 2012 .

Nicotine as a potential neuroprotective agent for Parkinson's disease

M. Quik, T. Bordia, X. Perez, 2012, Movement disorders : official journal of the Movement Disorder Society.

α6β2* and α4β2* Nicotinic Receptors Both Regulate Dopamine Signaling with Increased Nigrostriatal Damage: Relevance to Parkinson's Disease

M. Quik, T. Bordia, J. McIntosh, 2010, Molecular Pharmacology.

Long-Term Nicotine Treatment Differentially Regulates Striatal α6α4β2* and α6(Nonα4)β2* nAChR Expression and Function

S. Grady, M. Quik, T. Bordia, 2008, Molecular Pharmacology.

Chronic nicotine treatment differentially regulates striatal α 6 α 4 β 2* and α 6(non α 4) β 2* nAChR expression and function

S. Grady, M. Quik, T. Bordia, 2008 .

Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

M. Quik, T. Bordia, X. Perez, 2014, Pharmacology & therapeutics.

Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia

M. Quik, T. Bordia, X. Perez, 2014 .

Long‐term nicotine treatment down‐regulates α6β2* nicotinic receptor expression and function in nucleus accumbens

M. Quik, J. McIntosh, X. Perez, 2013, Journal of neurochemistry.

Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

S. Grady, M. Quik, X. Perez, 2011, Biochemical pharmacology.

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

M. Quik, T. Bordia, X. Perez, 2018, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.

M. Quik, T. Bordia, X. Perez, 2015, International review of neurobiology.

Long-Term Nicotine Exposure Depresses Dopamine Release in Nonhuman Primate Nucleus Accumbens

M. Quik, J. McIntosh, X. Perez, 2012, Journal of Pharmacology and Experimental Therapeutics.

Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias

T. Bordia, X. Perez, 2018, The European journal of neuroscience.

Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson’s Disease

X. Perez, 2015, Neuropsychology Review.

Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia

M. Quik, T. Bordia, X. Perez, 2016, Experimental Neurology.

Filtration disrupts synaptosomes during radiochemical analysis of serotonin uptake: Comparison with chronoamperometry in SERT knockout mice

A. Andrews, X. Perez, Anne M. Andrews, 2006, Journal of Neuroscience Methods.

Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

M. Quik, T. Bordia, X. Perez, 2017, Movement disorders : official journal of the Movement Disorder Society.

Pre‐synaptic dopaminergic compensation after moderate nigrostriatal damage in non‐human primates

M. Quik, N. Parameswaran, Luping Z. Huang, 2008, Journal of neurochemistry.

The striatal cholinergic system in l-dopa-induced dyskinesias

M. Quik, T. Bordia, X. Perez, 2018, Journal of Neural Transmission.

Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal

M. Quik, J. McIntosh, X. Perez, 2014, Pharmacology research & perspectives.

JPET # 194084 2 RUNNING TITLE PAGE Running Title : Long-term nicotine depresses dopamine release

M. Quik, J. McIntosh, X. Perez, 2012 .

α7 nicotinic receptor agonists reduce levodopa‐induced dyskinesias with severe nigrostriatal damage

M. Decker, M. Quik, T. Bordia, 2015, Movement disorders : official journal of the Movement Disorder Society.

Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter

C. Gerfen, G. Miller, J. Langston, 2007, Neurobiology of Disease.

Cortical nNOS neurons co-express the NK1 receptor and are depolarized by Substance P in multiple mammalian species

Jaime E. Heiss, M. Quik, T. Kilduff, 2012, Front. Neural Circuits.

Compensation in pre‐synaptic dopaminergic function following nigrostriatal damage in primates

S. Grady, M. Quik, S. McCallum, 2006, Journal of neurochemistry.

Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias

Jaime E. Heiss, M. Quik, T. Bordia, 2016, Neurobiology of Disease.

Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.

Michael O'Neill, Maryka Quik, M. Quik, 2007, Trends in pharmacological sciences.

Prominent Role of α3/α6β2* nAChRs in Regulating Evoked Dopamine Release in Primate Putamen: Effect of Long-Term Nicotine Treatment

M. Quik, N. Parameswaran, J. McIntosh, 2009, Molecular Pharmacology.